Berry John, Glasgow Sean C
Division of Colon and Rectal Surgery, Department of Surgery, Washington University School of Medicine, St. Louis, Missouri.
Clin Colon Rectal Surg. 2018 Nov;31(6):321-327. doi: 10.1055/s-0038-1668101. Epub 2018 Nov 2.
Human papillomavirus (HPV) infection is responsible for 4.3% of the global cancer burden. Since 2006, current HPV vaccines have reduced the prevalence of the virus in adolescent girls, reduced the prevalence of genital warts, and been proven to reduce the progression of anal intraepithelial neoplasia in men. Herein, we review the epidemiology, virology, and immunology behind the prophylactic HPV vaccines and current recommendations for its use. We also review future immune therapies being trialed for use against HPV-related cancers including anal cancer.
人乳头瘤病毒（HPV）感染导致了全球4.3%的癌症负担。自2006年以来，现有的HPV疫苗降低了青春期女孩中该病毒的流行率，降低了尖锐湿疣的发病率，并且已被证明可减少男性肛门上皮内瘤变的进展。在此，我们综述预防性HPV疫苗背后的流行病学、病毒学和免疫学，以及其目前的使用建议。我们还综述了正在试验用于治疗包括肛门癌在内的HPV相关癌症的未来免疫疗法。
